Although some centers now routinely use this agent as post allo-SCT maintenance for FLT3-ITD AML, the tolerability of this agent remains debatable and questions remain over the validity of these results in the era of patients routinely receiving midostaurin at induction pre allo-SCT (156). Here, FLT3 is linked to acute myeloid leukemia.